Generic Name and Formulations:
Potassium (as bicarbonate and citrate) 10mEq, 20mEq, 25mEq; effervescent tabs for soln; unflavored, cherry vanilla, orange cream, lemon citrus, cherry berry flavors.
Indications for EFFER-K:
Hypokalemia with or without metabolic alkalosis. Digitalis intoxication. Hypokalemic familial periodic paralysis. Prevention of potassium depletion when dietary intake is inadequate.
Take with food or immediately after a meal; sip slowly over 5–10 mins. 1 tab 1–4 times daily, based on patient requirement. Dissolve each 10mEq tab in 2–3oz of cold water or juice (if unflavored); dissolve each 20mEq tab in 3–4oz of cold water or juice (if unflavored); dissolve each 25mEq tab in 4oz of cold water or 12–16oz of cold juice (if unflavored).
Hyperkalemia. Chronic renal disease. Metabolic acidosis. Uncontrolled diabetes mellitus. Esophageal compression. Delayed gastric emptying. Intestinal obstruction/stricture. Peptic ulcer. Concomitant potassium-sparing diuretics (eg, spironolactone, triamterene).
Discontinue if GI bleed, ulceration, or other disturbances occur. Acidosis. Renal or cardiac disease. Monitor serum potassium and magnesium levels, renal function, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with potassium-sparing diuretics, ACE inhibitors, NSAIDs, beta-adrenergic blockers, heparin, low-salt foods, potassium-containing drugs, digitalis glycosides, others.
Hyperkalemia, nausea, vomiting, abdominal discomfort, diarrhea.
Tabs 10mEq, 20mEq—30; 25mEq—30, 100 (orange-flavored)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|